key: cord-0298980-7mu7scqv
authors: Koyuncu, A.; Mapemba, D.; Ciglenecki, I.; Gurley, E. S.; Azman, A. S.
title: Setting a course for preventing hepatitis E in low and lower-middle-income countries: A systematic review of burden and risk factors
date: 2020-11-30
journal: nan
DOI: 10.1101/2020.11.27.20239715
sha: dd550483cc654dcd4c429d1509e2345fdbfd2bd2
doc_id: 298980
cord_uid: 7mu7scqv

Background Hepatitis E virus is responsible for outbreaks of acute jaundice in Africa and Asia, many of which occur among displaced people or in crisis settings. While an efficacious vaccine for HEV has been developed, we lack key epidemiologic data needed to understand how best to use the vaccine for hepatitis E control in endemic countries. Methods We conducted a systematic review of articles published on hepatitis E in low and lower-middle-income countries (LMIC) in Africa and Asia. We searched PubMed, Scopus, and Embase databases to identify articles with data on anti-HEV IgG seroprevalence, outbreaks of HEV, or risk factors for HEV infection, disease, or death, and all relevant data were extracted. Using these data we describe the evidence around temporal and geographical distribution of HEV transmission and burden. We estimated pooled age-specific seroprevalence and assessed the consistency in risk factor estimates. Results We extracted data from 148 studies. Studies assessing anti-HEV IgG antibodies used 18 different commercial assays. Most cases of hepatitis E during outbreaks were not confirmed. Risk factor data suggested an increased likelihood of current or recent HEV infection and disease associated with fecal-oral transmission of HEV, as well as exposures to blood and animals. Conclusion Heterogeneity in diagnostic assays used and exposure and outcome assessment methods hinder public health efforts to quantify burden of disease and evaluate interventions over time and space. Prevention tools such as vaccines are available, but require a unified global strategy for hepatitis E control to justify widespread use.

Access to clean water and sanitation could significantly reduce the transmission of HEV in LMIC, but household-level water and sanitation interventions often require behavioral change and have had mixed results in outbreak control (5) . Outbreaks of HEV, many of which occur among displaced people or in crisis settings, are notoriously difficult to control in part due to the high proportion of asymptomatic and mildly symptomatic infections and limited options for clinical management of severe cases (3) . One potential intervention strategy to control HEV transmission is a recombinant vaccine, HEV239 (Hecolin ® ; Innovax, Xiamen, China), which has been shown to be safe and highly efficacious in preventing HEV infection due to genotype 4, with pan-genotype protection expected (6) . The World Health Organization (WHO) has not recommended the routine use of the vaccine in HEV endemic countries, citing a critical lack of epidemiologic data on the incidence of disease in the general population and in special subpopulations (7) .

In the absence of these data Hecolin is currently only recommended by WHO for consideration during HEV outbreaks, although at the time of writing this it has not been used in any outbreaks (7) .

Burden-of-disease data, combined with information on key risk factors for HEV infection and disease can spur the use of existing prevention tools that may be capable of substantially reducing morbidity and mortality due to HEV in LMIC. A lack of data on the burden and transmission patterns of HEV precludes investments into a global strategy for control for hepatitis E (8) . Given the clear pathway for WHO prequalification of the existing vaccine (9), a better understanding of the epidemiology of hepatitis E viruses is needed to set the agenda for global strategy and identify best practices to measure impact. Here we aim to review data on the epidemiology of hepatitis E in low and lower-middle-income countries in Africa and Asia through systematic reviews of three domains of evidence, first through a review of seroprevalence studies, second a review of reported outbreak size and geography, and finally a review of risk factors for infection, disease and death.

We searched PubMed, Scopus, and Embase to identify all studies with 'hepatitis E' in the article title that were published prior to November 2018, regardless of language. We uploaded search results to covidence (www.covidence.org), which we used to manage the subsequent steps of the review.

For both stages of study selection (abstract review, full text review) two independent reviewers screened each document for eligibility. All discrepancies between reviewers were reviewed by a third reviewer, who discussed with the original reviewers and decided upon the correct classification.

Studies were included if they satisfied the following inclusion criteria: (i) study in a lowincome or lower-middle-income country in Africa or Asia according to 2019 World Bank country classifications (10) ; and (ii) includes serosurvey data (anti-HEV IgG only, IgG and/or IgM) in populations without known liver disease; or (iii) includes an outbreak description of HEV genotype 1, 2, or unidentified genotype; or (iv) includes effect size estimates (e.g. odds ratio, risk ratio) for potential risk factors for current or recent infection (anti-HEV IgM or RNA), disease, or death. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239715 doi: medRxiv preprint Studies were excluded if they met any of the following criteria: (i) abstract or full-text not available; (ii) abstract or full-text not in French, English or Spanish; (iii) non-human study of HEV; (iv) diagnostic, viral genetics, or immunologic study; (v) case series with no controls for any outcome; (vi) commentary, perspective, or review article; (vii) studies with duplicate data.

A data extraction form developed by the authors was used to extract data from the fulltext of all included studies. A plot digitizer (https://apps.automeris.io/wpd/) was used if data were only presented graphically. To gauge the consistency of the data extraction and to identify common errors, 10% of all studies in the data abstraction phase were extracted independently by two reviewers, and any discrepancies in data extracted were resolved by discussion and consensus. We used lessons from discrepancies in extracted data to adjust previous extractions and to ensure that future extractions did not have those errors.

For studies reporting seroprevalence data, we extracted population type, lower and upper bounds for population age, diagnostic assay, test isotype (anti-HEV IgG or IgG+IgM), and the total number of samples tested and number of positive/negative samples. Within each study, data were extracted separately for each age stratum and unique population type: general population, blood donors, patients attending a hospital or clinic for non-liver related, non-pregnancy related issues, pregnant women, occupational groups exposed to animals (e.g. butchers, pig farmers), outbreak residents (i.e. individuals 7 identified in areas with an ongoing HEV outbreak) or other. Refugee and internally displaced populations that were not experiencing outbreaks were categorized as "other". If studies reported seroprevalence data from the same population using different assays including Wantai assays (Wantai BioPharm, Beijing, China; considered the most reliable commercially available assay at the time of writing), we only extracted seroprevalence data based on Wantai assays (11) .

For studies describing outbreaks, we extracted the date of the first and last cases reported in the outbreak, whether the outbreak occurred in a refugee or displaced persons camp, HEV genotype(s) identified, suspected/confirmed case definitions and laboratory confirmation methods, number of suspected cases with confirmatory testing, average age (mean or median) of cases, number of suspected/confirmed cases, and number of suspected/confirmed deaths. Data on the number of suspected/confirmed cases and deaths were extracted within stratum of where cases were identified, namely: at health facilities, in communities, in institutions (e.g. prisons, army barracks), and not reported. The number of suspected/confirmed cases and deaths was extracted for the general population and also separately for pregnant/postpartum women and children under the age of 5. If multiple studies described the same outbreak (overlapping outbreak dates in the same geographic area and population) the most comprehensive outbreak report was extracted. Studies describing the same outbreak were combined only if they presented unique data (e.g.

data on different subpopulations, number of deaths, etc.). All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239715 doi: medRxiv preprint

For studies including risk factors for infection, disease, or death, we extracted outcome definition and confirmation method, estimator of association (e.g. odds ratio, risk ratio), effect size, 95% confidence interval, reference category for the estimator, and whether the estimator was adjusted for any covariates using regression analysis or matching. If both odds ratios and risk ratios were presented for the same risk factor, we extracted odds ratios. If risk factor data were reported for different case definitions of infection/disease within the same study, we extracted the most conservative case definition. We categorized each risk factor into one of the following groups: water, sanitation, hygiene, food and drink (non-water), exposure to blood or blood products, exposure to animals, age, sex, or other. Current and recent HEV infection and disease was defined in three categories: serologic evidence of anti-HEV IgM or RNA with no accompanying symptoms ("confirmed infection"), symptoms consistent with hepatitis (e.g. jaundice, elevated liver enzymes) without any serologic testing ("suspected disease"), or symptoms consistent with hepatitis with confirmation by IgM or HEV RNA ("confirmed disease").

We examined trends in the number of seroprevalence studies conducted over time, as well as variability in seroprevalence by age, population type, and diagnostic assay. Agespecific seroprevalence was calculated using the median age of tested individuals for each seroprevalence estimate. Seroprevalence estimates with no data on population age were excluded from analysis of seroprevalence by age.

We estimated outbreak duration using the difference between the date of the first and last cases reported in each outbreak description. The case fatality risk (CFR) was calculated separately among suspected cases and confirmed cases, and was defined as the number of suspected/confirmed deaths divided by the number of suspected/confirmed cases.

We categorized risk factors based on the general consensus of the literature on factors that increase HEV infection/disease/death risk and those that are protective. Risk factors lacking a hypothesized direction of effect (e.g. ethnicity) or with an unspecified reference group were excluded from further analysis. Household water sources and type of sanitation facilities were categorized as improved or unimproved according to 2019 World Health Organization/United Nations Children's Fund standard categories (12) . A summary of risk factors and their corresponding exposures hypothesized to increase the likelihood of HEV infection/disease/death is provided in the Appendix (Supplemental Table 1 ). If studies reported unadjusted and adjusted estimates we included the adjusted estimates. We examined the proportion of risk factors that followed the hypothesized direction of effect (e.g. effect estimate >1 for risk factors hypothesized to increase risk) and the proportion that were statistically significant based on 95% confidence intervals or a p-value < 0.05.

After the exclusion of duplicates, our search identified 4,928 studies for abstract screening, of which 666 met the criteria for full-text review. We identified 148 studies that satisfied the inclusion criteria after full text review ( Figure 1 ). All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239715 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239715 doi: medRxiv preprint Among studies that reported assay manufacturer (85%; 77/91), anti-HEV IgG antibodies were assessed using 18 different commercial assays as well as in-house assays (e.g.

Walter Reed Army Institute of Research in-house assay). The most common assays used to assess seroprevalence were in-house assays (21%) ( preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239715 doi: medRxiv preprint Diagnostika, Germany) (15,18,28,32,43, 80, 82, 83, 87, 93, 94) with the Wantai assay becoming the most commonly used assay in studies conducted in the last 5 years of the review (2013-2017).

HEV seropositivity, in general, increased with age among all population groups except occupational groups exposed to animals ( Figure 3 ). All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239715 doi: medRxiv preprint 2017. Excludes seroprevalence estimates with no specified age bounds and 1 study with unspecified location. Population types include general population, blood donors, patients attending a hospital or clinic for non-liver related, non-pregnancy related issues (hospital), pregnant women, occupational groups exposed to animals (occupational), outbreak residents, or other. Black line represents the best fit linear trend between age and seropositivity.

Age-specific seroprevalence estimates, excluding occupational groups and outbreak residents, increased by age with all assays used, except Abbott (Supplemental Figure   1 ). Among outbreaks with reported locations (48/49), outbreaks were identified in Africa (43%) and Asia (57%), with over half of outbreaks reported from 3 countries: India (35%) (30, 106, 107, 109, 110, 114, 117, 121, 125, 128, [136] [137] [138] 141, 145, 147, 148) , Sudan (10%) (119, 133, 140, 143, 144) , and Uganda (8%) (78, 85, 108, 126, 129) . preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239715 doi: medRxiv preprint settlements (N=6) (50, 78, 111, 119, 123, 123) , with 31% of all suspected cases (24,341/77,372 suspected cases) identified in our review occurring in these settings.

Confirmatory serologic testing (i.e., IgM) was conducted for 10% of all suspected cases reported in outbreaks (7,956/77,372) , including 15 small outbreaks (<500 suspected cases) in which 100% of all suspected cases had confirmatory serologic testing (30, 82, 93, 113, 118, 121, 122, 125, 129, 134, 135, 140, (142) (143) (144) . Among outbreaks where at least some cases were laboratory confirmed (N=47), 94% of confirmed case definitions included serologic confirmation of HEV IgM and 21% included HEV RNA. Overall, 43% of all suspected cases were identified in health facilities, 42% were identified within the community, 1% were identified in institutions (e.g. military training camps, prisons), and 13% were identified in unknown locations.

Among studies reporting data on deaths (34/49), the CFR ranged from 0-28% among suspected cases (mean: 2; SD: 6) and 0-28% among confirmed cases (mean: 3; SD: 7).

Fewer outbreak reports had available data on deaths among pregnant women (20/48), and the CFR among pregnant women ranged from 0-33% among suspected cases (mean: 11; SD: 10) and 0-65% among confirmed cases (mean: 28; SD: 24) (50, 78, 82, 104, 106, 108, (112) (113) (114) 117, 119, 120, 123, 124, (126) (127) (128) (129) 140, 146) . The highest CFR (65%; 15 fatalities among 23 confirmed pregnant cases) was reported among pregnant women in an outbreak in Napak district, Uganda which had over 1,300 confirmed cases of HEV in the overall population in 2013-2014 (108).

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239715 doi: medRxiv preprint Based on the direction of effect estimates, 67% of effect estimates for water suggested increased risk of HEV with increased exposure to unimproved water sources and 33% of estimates showed the opposite trend or no effect (effect size = 0) (Figure 4 ). Effect estimates for sanitation and hygiene were similarly heterogeneous: 83% of sanitationrelated estimates suggested increased risk with exposure to unimproved sanitation, and 71% of hygiene-related effect estimates suggested increased risk due to poor hygiene practices (e.g., never washing hands after defecating, etc.). Among estimates reported with a measure of statistical significance (76/79), a higher proportion of estimates for sanitation were statistically significant (33%) compared to estimates for water (21%) or hygiene (29%).

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239715 doi: medRxiv preprint Table 1 ). CI: 95% Confidence Interval. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239715 doi: medRxiv preprint Excludes 9 risk factor estimates not reported with corresponding 95% confidence intervals.

Increased risk of HEV infection/disease (effect size >1) was identified in a majority of effect estimates related to exposures to food and drink (82% of estimates), blood (81%), and animals (72%). Food and drink exposures (N=33), were predominantly assessed with questions related to consumption of meat (42%) and juices/sodas (24%). The majority of assessed exposures to blood (N=16) were related to blood transfusions (38%) and recent injections (25%). The majority of assessed exposures to animals (N=25) were related to the presence of animals (pets or varmints) in compounds/homes (32%), occupational exposures (24%), any contact with animals (16%), and livestock ownership (16%). Only 21% (7/33) of effect estimates related to food/drink exposures were statistically significant, while 38% (6/16) of estimates for blood exposures and 20% (5/25) of estimates for animal exposures were significant.

The directionality of effect estimates was consistent with the hypothesis that older age increases risk of HEV infection/disease in 52% of estimates for confirmed disease and 54% of estimates for confirmed infection, as would be expected by chance. Effect estimates related to age were statistically significant for 40% (10/25) of estimates for confirmed disease and 8% (1/12) of estimates for confirmed infection. 82% (9/11) of estimates that were statistically significant suggested increased risk for confirmed HEV disease/infection with older age. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239715 doi: medRxiv preprint In 72% of estimates (13/18) males had a higher risk of infection/disease than females.

Among estimates reported with a measure of statistical significance (17/18), 41% were statistically significant.

Through a synthesis of published literature we highlight the persistent burden of hepatitis E genotypes 1 and 2 in LMICs and suggest that zoonotic and blood borne transmission may be contributing to this burden in addition to fecal-oral transmission.

Although studies on HEV burden have expanded geographically over time, existing data are insufficient to identify temporal or geographic trends in risk. Similar to other reviews, we note challenges in interpreting and comparing data from different studies due to variability in diagnostic assays used, definitions of suspected and confirmed cases of HEV (160) (161) (162) , and lack of standardized age groups used in analysis. Unified guidance and best practices for measuring disease burden and risk factors are urgently needed to generate evidence needed for developing a global strategy for hepatitis E control.

Given that most cases of hepatitis E are mild or asymptomatic and the lack of routine testing for hepatitis E among acute jaundice cases in LMICs, our knowledge on HEV burden of disease is largely limited to special studies and outbreak reports (163) . Gaps in burden of disease data identified by WHO's Strategic Advisory Group of Experts on Immunization (SAGE) in 2015 as barriers to widespread introduction of hepatitis E vaccine remain largely unaddressed (7) . A lack of data on the incidence of disease in the general population prevents the necessary investments in hepatitis E surveillance infrastructure, which cyclically limits our ability to quantify disease burden and advocate All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 30, 2020. ;

for expanded use of the existing vaccine. Notably, the SARS-CoV-2 pandemic provides an opportunity to break this cycle due to the increased number of representative population-based surveys that have been conducted (164) . Leveraging remnant samples from these studies could provide a cost-effective way of greatly increasing our understanding of the global burden of hepatitis E (165).

Our findings emphasize how a reliance on data from outbreak reports can obscure potentially important HEV transmission pathways. Trends suggestive of increased risk for infection and disease due to exposures to animals and consumption of meat suggest that HEV genotypes 3 and 4 may be responsible for some of the hepatitis E burden.

Our findings suggest that sporadic hepatitis cases in LMIC may also be due to blood borne transmission of HEV, which is most likely to be caused by the predominant circulating genotype within each population (151) . However, our ability to draw conclusions about the role of zoonotic and blood-borne transmission is limited given that only 27% of studies with data on risk factors adjusted for potentially confounding variables such as socioeconomic status. Our ability to identify key risk factors is further limited by the fact that most 'controls' in case-control studies were recruited on the basis of not having hepatitis E disease with the assumption that they were still at-risk. Some of these controls were almost certainly previously exposed to HEV, which would lead to reduced power, and in some cases bias, in estimates of risk factors (166) . A better understanding of the frequency of HEV infection due to transmission routes such as zoonotic transmission and blood-borne transmission in endemic countries may justify potentially life-saving interventions such as blood donor screening for HEV. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239715 doi: medRxiv preprint WHO has recommended the vaccine be considered as a strategy to prevent and mitigate outbreaks, particularly among high-risk groups such as pregnant women (7).

The current vaccine's three dose schedule given across 6 months introduces logistical constraints to rapidly deploying vaccines in outbreaks (167) . While reduced dose regimens may confer protection against HEV (6), the multi-year protracted outbreaks identified in our review suggest the potential for even a three dose regimen to substantially prevent morbidity and mortality among the world's most vulnerable populations. While we note that CFRs may be overestimated in studies relying on health facilities for case detection, the average case fatality risk among confirmed pregnant cases in outbreaks in this review was 9.3 times higher than confirmed cases in the general population. Field studies are urgently needed to evaluate the safety and effectiveness of the existing hepatitis E vaccine subpopulations such as refugees and pregnant women who are disproportionately affected by the burden of HEV. This review has several limitations. We did not conduct any formal risk of bias assessments, and did not exclude any studies on the basis of sample size. Trends in risk factor data may have been under or overestimated due to the inclusion of low quality estimates. We underestimated the number of HEV outbreaks in LMIC due to limited publishing of outbreaks in peer-reviewed journals and our exclusion of less formal outbreak reports, such as the WHO Outbreaks and Emergencies bulletin.

Outbreak reports were often based on research investigations of outbreak etiology rather than comprehensive assessments of outbreak size, leading to an underestimation of the burden of outbreaks. Age-specific seroprevalence curves stratified by population type were generated using data from diverse diagnostic assays All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239715 doi: medRxiv preprint which have varying sensitivity and specificity, and therefore may not represent true agespecific patterns. Finally, our ability to draw conclusions from risk factor data is limited given our inclusion of unadjusted and adjusted estimators collected from varying population types. Nevertheless, we identify key trends in the force of infection of HEV and risk factors for transmission that warrant further investigation in future studies.

Addressing outstanding gaps in our understanding of the epidemiology of HEV in LMICs is critical to justify the funds needed for expanded use of the vaccine following prequalification. Standardized guidelines defining best practices for study design and exposure and outcome measurement in hepatitis E research are needed to identify key areas with elevated incidence of HEV infection where the vaccine may be a costeffective tool to prevent avoidable morbidity and mortality. Guidelines are also needed to define a minimum set of risk factors for which data should be collected in all HEV outbreak investigations and risk factor studies, including: sociodemographic variables (e.g. SES, age, sex), WASH, and exposures to animals and blood. Broad control of hepatitis E with existing tools and strategies is possible, but requires a unified global strategy and the inclusion of hepatitis E in the agendas of researchers, public health authorities, and funders.

This work was supported by the Bill and Melinda Gates Foundation (INV-0166643; recipient AA). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 30, 2020. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239715 doi: medRxiv preprint

The global burden of hepatitis E virus genotypes 1 and 2 in 2005

The Global Prevalence of Hepatitis E Virus Infection and Susceptibility: A Systematic Review

World Health Organization

Hepatitis E. The Lancet

Hepatitis E: An emerging awareness of an old disease

A Large Outbreak of Hepatitis E among a Displaced Population in Darfur

Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial

Hepatitis E vaccine: WHO position Paper

Reactive and pre-emptive vaccination strategies to control hepatitis E infection in emergency and refugee settings: A modelling study

World Health Organization. Recommendations to assure the quality, safety and efficacy of recombinant hepatitis E vaccines

World Bank Country and Lending Groups -World Bank Data Help Desk

Two Generations of "Gold Standards": The Impact of a Decade in Hepatitis E Virus Testing Innovation on Population Seroprevalence

United Nations Children's Fund (UNICEF), World Health Organization. Progress on household drinking water, sanitation and hygiene 2000-2017: Special focus on inequalities

Unexpected elevated alanine aminotransferase, asparte aminotransferase levels and hepatitis e virus infection among persons who work with pigs in

com) Centre for Tropical Clinical Pharmacology and Therapeutics

The Association of Cytokines and Micronutrients with Hepatitis E Virus Infection During Pregnancy and the Postpartum Period in Rural Bangladesh. The American journal of tropical medicine and hygiene

Lack of evidence of hepatitis E virus infection among renal transplant recipients in a disease-endemic area

Investigation of hepatitis E outbreak among refugees

Increased risk of hepatitis E in sewage workers from India

High prevalence of hepatitis E in humans and pigs and evidence of genotype-3 virus in swine, Madagascar. The American journal of tropical medicine and hygiene

High prevalence of hepatitis E antibodies in pregnant Egyptian women

High hepatitis e seroprevalence among displaced persons in south sudan: Evidence of undetected transmission and implications for vaccination

High circulation of Hepatitis E virus in pigs and professionals exposed to pigs in Laos

Hepatitis E virus: the cause of a waterbourne hepatitis outbreak

Hepatitis E virus: can it be transmitted parenterally?

Hepatitis E virus superinfection in patients with chronic liver disease

Hepatitis E virus seroprevalence in three hyperendemic areas: Nepal, Bangladesh and southwest France

Hepatitis E virus seroprevalence in children living in rural Ghana. West African journal of medicine

Hepatitis E Virus Seroprevalence and Correlates of Anti-HEV IgG Antibodies in the Rakai District

Hepatitis E virus seroprevalence among hemodialysis and hemophiliac patients in Tunisia (North Africa)

Hepatitis E virus seroepidemiology: a post-earthquake study among blood donors in Nepal

Hepatitis E virus is highly prevalent among pregnant women in Gabon, central Africa, with different patterns between rural and urban areas

Hepatitis E virus infections in swine and swine handlers in Vellore, Southern India. The American journal of tropical medicine and hygiene

Hepatitis E virus infections in HIV-infected patients in Ghana and Cameroon

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology

Hepatitis E virus infection may be transmitted through blood transfusions in an endemic area

Hepatitis E virus infection is highly prevalent among pregnant women in

Hepatitis E virus infection in Thai troops deployed with U.N. peacekeeping forces. Military medicine

Hepatitis E virus infection in Ghanaian blood donors -the importance of immunoassay selection and confirmation. Vox sanguinis

Hepatitis e virus infection in fulminant hepatitis patients and an apparently healthy population in Bangladesh. The American journal of tropical medicine and hygiene

Hepatitis E virus infection and acute-on-chronic liver failure in West Africa: a case-control study from The Gambia

Hepatitis E virus infection among pig handlers in Accra

Hepatitis E virus IgG in serum of pregnant women

Hepatitis E virus epidemiology among HIV-infected women in an urban area in Tanzania. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases

Hepatitis E virus antibody prevalence, RNA frequency, and genotype among blood donors in Cambodia (Southeast Asia)

Hepatitis E epidemic, Uganda. Emerging infectious diseases

Hepatitis E antibody seroconversion without disease in highly endemic rural Egyptian communities

Hepatitis E antibodies in Egyptian adolescent females: their prevalence and possible relevance

First report of hepatitis E virus viremia in healthy blood donors from Nepal

First documented outbreak of hepatitis E virus transmission in Java

Exposer rate of hepatitis E (IgG) in a selected population of children and adults in Karachi

Examination for hepatitis E virus in wastewater treatment plants and workers by nested RT-PCR and ELISA

Evidence of person-to-person transmission of hepatitis E virus during a large outbreak in Northern Uganda. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Evidence of increased Hepatitis E virus exposure in Lao villagers with contact to ruminants

Evidence in favour of high infection rate with hepatitis E virus among young children in India

Epidemiology of hepatitis E virus infection in Western India

Epidemiology of hepatitis E virus infection during pregnancy in Benin. Tropical medicine & international health

Epidemiology of hepatitis E virus in an urban community in Dhaka city

Epidemiology and risk factors of incident hepatitis E virus infections in rural Bangladesh

Epidemiology and associated risk factors of hepatitis e virus infection in plateau state

Epidemic of hepatitis E in a military unit in Abbottabad

Epidemic and sporadic hepatitis E virus transmission in West Kalimantan (Borneo), Indonesia. The American journal of tropical medicine and hygiene

Detection of IgM and IgG antibodies against hepatitis E virus in donated blood bags from a national voluntary blood bank in Metro Manila

Clinicolaboratory study of mother-to-neonate transmission of hepatitis E virus in Egypt

Changing scenario of hepatitis A virus and hepatitis E virus exposure among the primitive tribes of Andaman and Nicobar Islands, India over the 10-year period 1989-99

Changing epidemiology of hepatitis A and hepatitis E in urban and rural India (1982-98)

Age-wise exposure rates to hepatitis e virus in a southern Indian patient population without liver disease. The American journal of tropical medicine and hygiene

Acute sporadic hepatitis E in Sudanese children: analysis based on a new western blot assay. The Journal of infectious diseases

A serological study of intrafamilial spread from patients with sporadic hepatitis E virus infection

A large outbreak of hepatitis E among a displaced population in Darfur, Sudan, 2004: the role of water treatment methods. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Epidemic hepatitis E: serological evidence for lack of intrafamilial spread

Water-borne hepatitis E virus epidemic in Islamabad, Pakistan: a common source outbreak traced to the malfunction of a modern water treatment plant. The American journal of tropical medicine and hygiene

Surveillance at Private Laboratories Identifies Small Outbreaks of Hepatitis E in Urban Bangladesh. The American journal of tropical medicine and hygiene

Seroepidemiology of a recent outbreak of Hepatitis E in urban Shimla

Seroepidemiology and role of polymerase chain reaction to detect viremia in an epidemic of hepatitis E in Western India

Risk factors, person, place and time characteristics associated with Hepatitis E Virus outbreak in Napak District

Outbreak of waterborne hepatitis E in

Outbreak of Viral Hepatitis E in a

Outbreak of Hepatitis E Virus Infection in Displaced Persons Camps in Diffa Region

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Outbreak of enterically-transmitted hepatitis due to hepatitis A and hepatitis E viruses

Outbreak of acute viral hepatitis due to hepatitis E virus in Hyderabad. Indian journal of medical microbiology

Outbreak of acute hepatitis E virus infection among military personnel in northern Ethiopia

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Investigation of an epidemic of Hepatitis E in Nellore in south India. Tropical medicine & international health

Imported hepatitis e virus, central african republic

High mortality associated with an outbreak of hepatitis E among displaced persons in Darfur, Sudan. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Hepatitis E, Central African Republic. Emerging infectious diseases

Hepatitis E virus: A leading cause of waterborne viral hepatitis in Northwest Districts of Punjab, India

Hepatitis E virus in Indonesia

Hepatitis E outbreak, Dadaab refugee camp

Hepatitis e outbreak among refugees from south sudan -Gambella

Hepatitis E infection in children: study of an outbreak

epidemiology and challenges to control in a setting of seminomadic pastoralism

Emerging infectious diseases

Hepatitis E epidemic with bimodal peak in a town of north India

Hepatitis E as a cause of acute jaundice syndrome in northern Uganda

First documented outbreak of Hepatitis e in Northern Cameroon

Epidemiological and molecular analyses of a non-seasonal outbreak of acute icteric hepatitis E in Bangladesh

Contrasting roles of rivers and wells as sources of drinking water on attack and fatality rates in a hepatitis E epidemic in Somalia. The American journal of tropical medicine and hygiene

Concomitant outbreaks of yellow fever and hepatitis E virus in Darfur States

Clinical and epidemiological aspects of a hepatitis E outbreak in Bangui, Central African Republic

Association of hepatitis E virus with an outbreak of hepatitis at a military training camp in Nepal

An outbreak of viral hepatitis E: role of community practices

An outbreak of hepatitis E virus infection caused by genotype 1 in an urban setting in eastern India: a probe into risk factors for transmission. VirusDisease

An outbreak of hepatitis E tracked to a spring in the foothills of the Himalayas

An outbreak of hepatitis E in an urban area of Bangladesh

An outbreak of hepatitis E and high maternal mortality at Port Sudan, Eastern Sudan. Pathogens and global health

An institutional outbreak of hepatitis E--reported first time from Calcutta city

An epidemic outbreak of hepatitis E in Yangon of Myanmar: antibody assay and animal transmission of the virus. Acta pathologica japonica

Acute hepatitis E infection during the 1988 floods in Khartoum

A Single Lineage of Hepatitis E Virus Causes Both Outbreaks and Sporadic Hepatitis in Sudan

A large waterborne viral hepatitis E epidemic in Kanpur

A large outbreak of Hepatitis E virus genotype 1 infection in an urban setting in Chad likely linked to household level transmission factors

A hepatitis E outbreak caused by a temporary interruption in a municipal water treatment system

Role of travel as a risk factor for hepatitis E virus infection in a disease-endemic area

Sporadic acute hepatitis caused by hepatitis E virus in Egyptian adults. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Seroprevalence of hepatitis E in swine abattoir workers. African health sciences

Risk Factors Associated with Blood Exposure for Sporadic Hepatitis E in Dhaka, Bangladesh. The American journal of tropical medicine and hygiene

Risk factors and immune response to hepatitis E viral infection among acute hepatitis patients in Assiut, Egypt. The Egyptian journal of immunology

Novel risk factors associated with hepatitis E virus infection in a large outbreak in northern Uganda: results from a case-control study and environmental analysis. The American journal of tropical medicine and hygiene

High viral load and deregulation of the progesterone receptor signaling pathway: association with hepatitis E-related poor pregnancy outcome

Hepatitis E Virus Superinfection and Clinical Progression in Hepatitis B Patients

Epidemiology and clinical features of sporadic hepatitis E as compared with hepatitis A. The American journal of gastroenterology

Detection of Genotype 1a and 1f of Hepatitis E Virus in Patients Treated at Tertiary Care Hospitals in Central India

An exploratory case control study of risk factors for hepatitis E in rural Bangladesh

Protective role of humoral immune responses during an outbreak of hepatitis E in Egypt

The global epidemiology of hepatitis E virus infection: A systematic review and meta-analysis

The global burden of hepatitis E outbreaks: a systematic review -Hakim -2017 -Liver International -Wiley Online Library

A systematic review of the epidemiology of hepatitis E virus in Africa

Hepatitis E should be considered a neglected tropical disease

Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. medRxiv

A Global lmmunological Observatory to meet a time of pandemics

Patterns of bias due to differential misclassification by case-control status in a casecontrol study

High Hepatitis E Seroprevalence Among Displaced Persons in South Sudan